KAPA Kairos Pharma, LTD.
Pharmaceutical Preparations · NYSE · SEC CIK 1962011 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-26.3%
TTM EPS YoY83.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-110.8%
ROA-102.8%
ROIC (approx.)-363.5%
Asset turnover—
Leverage & solvency
Liabilities / assets11.3%
Debt / equity0.00x
Current ratio6.77x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.64x
Accruals ratio-36.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $892,000 | $619,000 | $684,000 | $538,000 | $608,000 | $496,000 | $493,000 | $172,000 |
| SG&A expense | $1.12M | $798,000 | $1.01M | $877,000 | $827,000 | $960,000 | $773,000 | $1.27M |
| Operating income | -$2.01M | -$1.42M | -$1.69M | -$1.42M | -$1.44M | -$1.46M | -$1.27M | -$1.45M |
| Interest expense | — | — | — | — | — | — | — | $0 |
| Net income | -$1.98M | -$1.39M | -$1.65M | -$1.36M | -$1.40M | -$1.42M | -$1.26M | -$980,000 |
| EPS (basic) | -0.59 | -0.06 | -0.08 | — | -0.48 | -0.08 | -0.08 | — |
| EPS (diluted) | -0.59 | -0.06 | -0.08 | — | -0.48 | -0.08 | -0.08 | — |
| Weighted avg. shares (diluted) | 3.35M | 21.42M | 21.01M | — | 2.89M | 17.21M | 15.88M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $3.12M | $2.63M | $3.67M | $4.49M | $5.58M | $3.03M | $3.62M | $1.27M |
| Current assets | $3.35M | $3.17M | $4.44M | $5.39M | $6.66M | $4.84M | $6.05M | $4.17M |
| Intangibles | — | $191,000 | $22,000 | $62,000 | $102,000 | $142,000 | $182,000 | $222,000 |
| Total assets | $4.37M | $4.46M | $5.74M | $6.54M | $8.07M | $6.67M | $7.94M | $5.77M |
| Current liabilities | $495,000 | $265,000 | $431,000 | $199,000 | $402,000 | $676,000 | $805,000 | $992,000 |
| Total liabilities | $495,000 | $265,000 | $431,000 | $199,000 | $402,000 | $676,000 | $805,000 | $992,000 |
| Shareholders' equity | $3.88M | $4.19M | $5.31M | $6.34M | $7.66M | $6.00M | $7.13M | $4.78M |
| Shares outstanding | 3.73M | 21.42M | 21.41M | 2.97M | 20.82M | 17.74M | 15.83M | 13.74M |
| Cash flow statement | ||||||||
| Operating cash flow | -$979,000 | -$1.01M | -$1.04M | -$1.08M | -$838,000 | -$805,000 | -$714,000 | -$1.80M |
| Financing cash flow | $1.48M | -$37,000 | $220,000 | $0 | $3.38M | $223,000 | $3.06M | -$142,000 |
Free plan shows the latest 8 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.